Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The GLITTER study is comprised of four key components: Team, Technology, Education, and Peer Resources. The aim of the GLITTER Study is to improve the metabolic control rate in patients with type 1 diabetes through a comprehensive management approach.

Who May Be Eligible (Plain English)

Who May Qualify: 1\. Patients with type 1 diabetes of all age groups, regardless of disease duration. The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion. 1. Clinically diagnosed as Type 1 Diabetes by a specialist physician. 2. Meet any one of the following criteria: A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L 3. Meet any one of the following criteria: A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1\. Patients with type 1 diabetes of all age groups, regardless of disease duration. The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion. 1. Clinically diagnosed as Type 1 Diabetes by a specialist physician. 2. Meet any one of the following criteria: A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L 3. Meet any one of the following criteria: A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies

Treatments Being Tested

BEHAVIORAL

GLITTER comprehensive management

The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.

Locations (10)

Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, Beijing Municipality, China
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, China
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, Hunan, China
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University
Chengdu, Sichuan, China
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Hangzhou, Zhejiang, China